Intra-arterial Chemotherapy Combined with Radiotherapy and Immunotherapy for HNSCC
Trial statusRecruiting
Trial phasePhase 2
Trial typeInterventional
Biological sexAll
Age18+
SponsorBeijing Tongren Hospital
About this trial
This study pioneers a novel approach by integrating a new auxiliary chemo-immunotherapy regimen, which is then followed by an evaluation of the potential for surgical resection. For those patients who remain non-resectable, a tailored treatment plan is proposed, consisting of arterial infusion chemotherapy in conjunction with radiotherapy, succeeded by a series of immune checkpoint inhibitors. The efficacy and safety of this integrated therapeutic strategy are meticulously assessed, with the goal of enhancing survival outcomes for patients with T4bNanyM0 HNSCC.
Eligibility criteria
Qualifiers
Patients with T4bNanyM0 Head and neck squamous cell carcinoma (hypopharyngeal cancer, laryngeal cancer, oropharyngeal cancer or oral cavity) with a confirmed diagnosis by histology and/or cytology;
Expected survival ≥3 months, with adequate organ function;
Investigators believe they can safely receive treatment with PD-1 combined with platinum and albumin-bound paclitaxel;
Age ≥18 years;
Disqualifiers
Patients with a history of prior immunotherapy, radiotherapy, and treatment with EGFR monoclonal antibodies;
Patients with a history of other (including unknown primary) malignant tumors within the past 5 years;
Patients who are intolerant to radiotherapy post-surgery;
Patients known to be allergic to the study medication or its active ingredients, excipients;
Trial design
Treatments tested in this trial
- Tislelizumab-jsgr
- Cisplatin
- Albumin-Bound Paclitaxel
- Radiotherapy
Treatment groups
50 Participants
are divided into 1 treatment groupSponsors and collaborators
Source ClinicalTrials.gov